Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Analyst Upgrades and Downgrades

EXAS has been the subject of several research reports. Cowen cut their price objective on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a research report on Wednesday, August 3rd. Citigroup lowered their target price on Exact Sciences from $65.00 to $50.00 and set a "neutral" rating for the company in a research note on Wednesday, August 3rd. Robert W. Baird lowered their price objective on shares of Exact Sciences from $90.00 to $75.00 and set an "outperform" rating for the company in a research report on Wednesday, August 3rd. Evercore ISI upped their price objective on shares of Exact Sciences to $65.00 in a research report on Tuesday. Finally, The Goldman Sachs Group reduced their price target on Exact Sciences from $100.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, April 19th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $71.00.

Exact Sciences Stock Down 6.4 %

Shares of EXAS Stock traded down $2.89 during trading on Thursday, reaching $42.24. The company's stock had a trading volume of 176,588 shares, compared to its average volume of 1,877,212. The company has a market cap of $7.47 billion, a price-to-earnings ratio of -10.67 and a beta of 1.32. Exact Sciences has a one year low of $35.34 and a one year high of $108.99. The business has a fifty day moving average price of $44.23 and a 200-day moving average price of $58.37. The company has a quick ratio of 2.23, a current ratio of 2.48 and a debt-to-equity ratio of 0.70.

Insider Activity

In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the firm's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the transaction, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,722,754.52. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the business's stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now owns 60,318 shares of the company's stock, valued at $2,722,754.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm's stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now owns 60,318 shares in the company, valued at $2,420,561.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,701 shares of company stock valued at $251,872. 1.30% of the stock is owned by insiders.